Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

BACKGROUND: Dual blockade of HER2 promises increased pathological complete response (pCR) rate compared with single blockade in the presence of chemotherapy for HER2-positive (+) primary breast cancer. Many questions remain regarding optimal duration of treatment and combination impact of endocrine...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, N., Toi, M., Yamamoto, N., Iwata, H., Kuroi, K., Bando, H., Ohtani, S., Takano, T., Inoue, K., Yanagita, Y., Kasai, H., Morita, S., Sakurai, T., Ohno, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996004/
https://www.ncbi.nlm.nih.gov/pubmed/29445928
http://dx.doi.org/10.1007/s12282-018-0839-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996004/
https://www.ncbi.nlm.nih.gov/pubmed/29445928
http://dx.doi.org/10.1007/s12282-018-0839-7

Ejemplares similares